Cancer Family
Hematopoietic and Lymphatic System Neoplasm
CI-CAN-00000022Explore in graph →
Non-malignant4,301 active trials98 approved drugs1,010 evidence items
- NCIt
- C35813
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000022Explore in graph →
Clinical trials
18,832 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02004522 | A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO) | completed | Phase 3 | 319 | SecuraBioINDUSTRY | 11 | Sep 21, 2023 | clinicaltrials |
| NCT02049515 | A Phase 3 Extension Study of Duvelisib and Ofatumumab in Participants With CLL/SLL Previously Enrolled in Study IPI-145-07 | completed | Phase 3 | 99 | SecuraBioINDUSTRY | 11 | Sep 21, 2023 | clinicaltrials |
| NCT02312258 |
| A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT) |
| completed |
| Phase 3 |
| 706 |
| TakedaINDUSTRY |
| 35 |
| Sep 21, 2023 |
| clinicaltrials |
| NCT02140242 | Comparison Between Two Dose Levels of Daunorubicin and Between One vs. Two Induction Cycles for Adult Patients With AML(DaunoDouble) | completed | Phase 3 | 721 | Technische Universität DresdenOTHER | 2 | Sep 15, 2023 | clinicaltrials |
| NCT01951885 | Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention | completed | Phase 3 | 101 | Case Comprehensive Cancer CenterOTHER | 1 | Sep 11, 2023 | clinicaltrials |
| NCT03759093 | CURATE.AI Optimized Modulation for Multiple Myeloma | unknown | Phase 2 / Phase 3 | 20 | National University Hospital, SingaporeOTHER | 1 | Sep 6, 2023 | clinicaltrials |
| NCT05784870 | A Study of Shengxuening Tablet in the Treatment of Chemotherapy-related Anemia in Hematologic Tumors | unknown | Phase 3 | 168 | Zhongnan HospitalOTHER | 1 | Aug 25, 2023 | clinicaltrials |
| NCT00078949 | Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma | completed | Phase 3 | 849 | NCIC Clinical Trials GroupNETWORK | 3 | Aug 23, 2023 | clinicaltrials |
| NCT02755597 | A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy(Bellini) | completed | Phase 3 | 291 | AbbVieINDUSTRY | 16 | Aug 22, 2023 | clinicaltrials |
| NCT03512197 | A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML) | completed | Phase 3 | 511 | Novartis PharmaceuticalsINDUSTRY | 20 | Aug 21, 2023 | clinicaltrials |
| NCT02536300 | Dose Optimization Study of Idelalisib in Follicular Lymphoma | terminated | Phase 3 | 96 | Gilead SciencesINDUSTRY | 10 | Aug 14, 2023 | clinicaltrials |
| NCT00488605 | H-9926-LCH III: Treatment Protocol of the Third International Study for Langerhans Cell Histiocytosis | withdrawn | Phase 3 | 0 | University of New MexicoOTHER | 1 | Aug 3, 2023 | clinicaltrials |
| NCT05313958 | Treateament of Newly Diagnosed Acute Monocytic Leukemia in Children(SCCLG-M5) | unknown | Phase 2 / Phase 3 | 43 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jul 27, 2023 | clinicaltrials |
| NCT05020392 | Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma | unknown | Phase 3 | 24 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 25, 2023 | clinicaltrials |
| NCT01850524 | IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma | completed | Phase 3 | 705 | Millennium Pharmaceuticals, Inc.INDUSTRY | 7 | Jul 21, 2023 | clinicaltrials |
| NCT02665065 | Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia(SIERRA) | active not recruiting | Phase 3 | 153 | Actinium PharmaceuticalsINDUSTRY | 2 | Jul 19, 2023 | clinicaltrials |
| NCT00046930 | Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia | completed | Phase 3 | 449 | Eastern Cooperative Oncology GroupNETWORK | 2 | Jul 5, 2023 | clinicaltrials |
| NCT05931263 | A Randomized Clinical Trial Comparing Chi-BEAM With BEAM Regimen Combined With ASCT for the Treatment of ND PTCL | recruiting | Phase 3 | 104 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 5, 2023 | clinicaltrials |
| NCT00003389 | Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma | completed | Phase 3 | 854 | Eastern Cooperative Oncology GroupNETWORK | 3 | Jun 29, 2023 | clinicaltrials |
| NCT01063179 | Velcade, Melphalan, Prednisone And Thalidomide Versus Velcade, Melphalan, Prednisone in Multiple Myeloma Patients | completed | Phase 3 | 511 | Fondazione EMN Italy OnlusOTHER | 1 | Jun 29, 2023 | clinicaltrials |
| NCT03719534 | Haplo HCT vs Haplo-cord HCT for Patients With AML | completed | Phase 3 | 134 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jun 27, 2023 | clinicaltrials |
| NCT00002868 | Interferon-alfa With or Without Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia | completed | Phase 3 | 744 | Eastern Cooperative Oncology GroupNETWORK | 2 | Jun 22, 2023 | clinicaltrials |
| NCT02285062 | Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma(ROBUST) | completed | Phase 3 | 570 | CelgeneINDUSTRY | 21 | Jun 22, 2023 | clinicaltrials |
| NCT00002514 | Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission | completed | Phase 3 | 1,929 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 18, 2023 | clinicaltrials |
| NCT00003764 | Fludarabine With or Without Cyclophosphamide in Treating Patients With Chronic Lymphocytic Leukemia | completed | Phase 3 | 280 | Eastern Cooperative Oncology GroupNETWORK | 4 | Jun 18, 2023 | clinicaltrials |
| NCT00049517 | Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With AML Leukemia | completed | Phase 3 | 657 | Eastern Cooperative Oncology GroupNETWORK | 2 | Jun 15, 2023 | clinicaltrials |
| NCT04649060 | Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma(LIGHTHOUSE) | terminated | Phase 3 | 54 | Oncopeptides ABINDUSTRY | 11 | Jun 8, 2023 | clinicaltrials |
| NCT05188326 | Efficacy of 5-Aza for Post-Remission Therapy of Acute Myeloid Leukemia (AML) in Elderly Patients | completed | Phase 3 | 54 | Associazione Qol-oneOTHER | 1 | Jun 8, 2023 | clinicaltrials |
| NCT01734928 | Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma(OPTIMISMM) | completed | Phase 3 | 559 | CelgeneINDUSTRY | 22 | Jun 6, 2023 | clinicaltrials |
| NCT02516696 | BiRd vs. Rd as Initial Therapy in Multiple Myeloma(BiRd vs Rd) | terminated | Phase 3 | 12 | Weill Medical College of Cornell UniversityOTHER | 1 | Jun 5, 2023 | clinicaltrials |
| NCT04578613 | ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL | unknown | Phase 3 | 218 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | Jun 5, 2023 | clinicaltrials |
| NCT05264883 | Venetoclax+HMA+Aclarubicin Versus Venetoclax+HMA in Treatment-Naive Elderly Patients With AML | unknown | Phase 3 | 170 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | May 30, 2023 | clinicaltrials |
| NCT01596621 | A Study of Bendamustine in the Treatment of Chinese Participants With Indolent Non-Hodgkin Lymphoma Refractory to Rituximab Treatment | completed | Phase 3 | 102 | Teva Branded Pharmaceutical Products R&D, Inc.INDUSTRY | 1 | May 26, 2023 | clinicaltrials |
| NCT05876832 | A Study of XY0206 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory AML With FLT3-ITD-Mutation (ALIVE) | not yet recruiting | Phase 3 | 312 | Shijiazhuang Yiling Pharmaceutical Co. LtdINDUSTRY | 0 | May 26, 2023 | clinicaltrials |
| NCT00129090 | Mega-CHOEP: Conventional Chemo Vs HD Chemo Followed by Auto SCT in Younger Pts With Aggressive Non-Hodgkin's Lymphoma | completed | Phase 3 | 450 | German High-Grade Non-Hodgkin's Lymphoma Study GroupOTHER | 1 | May 25, 2023 | clinicaltrials |
| NCT05179733 | The Efficacy and Safety of ZR2 Versus R-miniCHOP in the Treatment of Unfit or Frail de Novo Diffuse Large B-cell Lymphoma Patients Aged Older Than or Equal to 70 Years | unknown | Phase 3 | 280 | Ruijin HospitalOTHER | 1 | May 23, 2023 | clinicaltrials |
| NCT00413439 | Safety, Efficacy and Pharmacokinetics of an Antifungal in Patients Undergoing Chemotherapy | completed | Phase 2 / Phase 3 | 18 | Basilea PharmaceuticaINDUSTRY | 1 | May 10, 2023 | clinicaltrials |
| NCT01657604 | TKI and Interferon Alpha Evaluation Initiated by the German Chronic Myeloid Leukemia Study Group - the TIGER Study(TIGER) | completed | Phase 3 | 717 | University of JenaOTHER | 3 | May 10, 2023 | clinicaltrials |
| NCT02890784 | Dasatinib Holiday for Improved Tolerability(DasaHIT) | completed | Phase 3 | 291 | University of JenaOTHER | 1 | May 10, 2023 | clinicaltrials |
| NCT03800758 | Expressive Helping for Stem Cell Transplant Patients | completed | Phase 3 | 405 | Northwestern UniversityOTHER | 1 | May 6, 2023 | clinicaltrials |
| NCT03948035 | Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM | active not recruiting | Phase 3 | 576 | Wuerzburg University HospitalOTHER | 2 | May 6, 2023 | clinicaltrials |
| NCT04333108 | Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment | unknown | Phase 3 | 140 | AB ScienceINDUSTRY | 8 | May 6, 2023 | clinicaltrials |
| NCT01685814 | Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance | unknown | Phase 3 | 406 | Wuerzburg University HospitalOTHER | 1 | Apr 27, 2023 | clinicaltrials |
| NCT03416179 | A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia(BRIGHT AML1019) | completed | Phase 3 | 730 | PfizerINDUSTRY | 22 | Apr 21, 2023 | clinicaltrials |
| NCT05431179 | A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma | withdrawn | Phase 3 | 0 | Oncternal Therapeutics, IncINDUSTRY | 0 | Apr 21, 2023 | clinicaltrials |
| NCT02756611 | A Study to Evaluate the Efficacy of Venetoclax Monotherapy in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL)(VENICE I) | completed | Phase 3 | 258 | AbbVieINDUSTRY | 21 | Apr 10, 2023 | clinicaltrials |
| NCT05802992 | The Efficacy and Safety of Colchicine Combined With Conventional Therapy in Multiple Myeloma Patients | unknown | Phase 3 | 30 | Affiliated Hospital of Nantong UniversityOTHER | 1 | Apr 7, 2023 | clinicaltrials |
| NCT05805098 | Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AML(VHA) | recruiting | Phase 2 / Phase 3 | 60 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Apr 7, 2023 | clinicaltrials |
| NCT00005585 | Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia | completed | Phase 3 | 838 | Children's Oncology GroupNETWORK | 6 | Apr 6, 2023 | clinicaltrials |
| NCT00005596 | Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia | completed | Phase 3 | 1,076 | Children's Oncology GroupNETWORK | 6 | Apr 6, 2023 | clinicaltrials |
Data updated 24 days agoSource updated Sep 21, 2023source: clinicaltrials